Neuroendocrine tumors are a heterogeneous group of tumors originating in various
anatomic locations. The management of this disease poses a significant challenge because …

Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity
for production of hormones and vasoactive peptides. Because of their perceived rarity, NETs …

Systemic therapies established in the management of patients with neuroendocrine tumors
(NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent …

Importance Multiple therapies are currently available for patients with neuroendocrine
tumors (NETs), yet many therapies have not been compared head-to-head within …

Neuroendocrine neoplasms are rare tumors that display marked heterogeneity with varying
natural history, biological behavior, response to therapy and prognosis. Their management …

Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with
symptoms of hormone secretion may require specific medical interventions to control those …

Purpose There are few effective therapies for pancreatic neuroendocrine tumors (PNETs).
Recent placebo-controlled phase III trials of the mammalian target of rapamycin (mTOR) …

Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011
guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances …

Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors with
complicated treatment options that depend on pathological grading, clinical staging, and …

Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse
neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract …